FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Daniel Budman

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Daniel R Budman; Anthony Calabro; Lisa Rosen; Martin Lesser
Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
Daniel R Budman; Anthony Calabro; Julia Tai; Veena John
The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.
Lyndsay N Harris; Gloria Broadwater; Maysa Abu-Khalaf; David Cowan; Ann D Thor; Daniel R Budman; Constance T Cirrincione; Donald A Berry; Eric P Winer; Clifford Hudis; Daniel F Hayes; Paula Friedman; Matthew Ellis; Lynn Dressler
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Daniel Budman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Daniel R Budman; Anthony Calabro; Lisa Rosen; Martin Lesser
Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
Anti-cancer drugs 2012;23(3):272-9.
2011: Daniel R Budman; Anthony Calabro; Julia Tai; Veena John
The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.
Investigational new drugs 2011;29(6):1224-9.
2009: Lyndsay N Harris; Gloria Broadwater; Maysa Abu-Khalaf; David Cowan; Ann D Thor; Daniel R Budman; Constance T Cirrincione; Donald A Berry; Eric P Winer; Clifford Hudis; Daniel F Hayes; Paula Friedman; Matthew Ellis; Lynn Dressler
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3430-6.
2009: M F Barginear; M Leung; Daniel R Budman
The hedgehog pathway as a therapeutic target for treatment of breast cancer.
Breast cancer research and treatment 2009;116(2):239-46.
2009: Myra F Barginear; Martin Lesser; Meredith Lukin Akerman; Marianna Strakhan; Iuliana Shapira; Thomas Bradley; Daniel R Budman
Need for inferior vena cava filters in cancer patients: a surrogate marker for poor outcome.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2009;15(3):263-9.
2008: Anthony Calabro; Julia Tai; Steven Allen; Daniel R Budman
In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia.
Anti-cancer drugs 2008;19(7):705-12.
2008: Michael P DiGiovanna; David F Stern; Susan M Edgerton; Gloria Broadwater; Lynn Dressler; Daniel R Budman; I Craig Henderson; Larry Norton; Edison Liu; Hyman Muss; Donald A Berry; Daniel F Hayes; Ann D Thor
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(14):2364-72.
2008: M F Barginear; L Donahue; Steven Allen; Daniel R Budman; Thomas Bradley; M Bhaskaran; Iuliana Shapira
Heparin-induced thrombocytopenia complicating hemodialysis.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2008;14(1):105-7.
2007: Hyman Muss; Donald A Berry; Constance Cirrincione; Daniel R Budman; I Craig Henderson; Marc L Citron; Larry Norton; Eric P Winer; Clifford Hudis
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3699-704.
2007: Daniel R Budman; Julia Tai; Anthony Calabro
Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro.
Breast cancer research and treatment 2007;104(1):93-101.
2007: Stuart M Lichtman; Hans Wildiers; Etienne Chatelut; Christopher Steer; Daniel R Budman; Vicki A Morrison; Brigitte Tranchand; Iuliana Shapira; Matti Aapro
International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(14):1832-43.
2007: Samit Hirawat; Jonathan E Kolitz; Stuart M Lichtman; Steven Allen; Gina Villani; Alma Gonzales; Marjorie Fricano; Daniel R Budman
A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabine.
Cancer investigation 2007;25(3):148-53.
2006: Julia Mandelblat; Tayyaba Bashir; Daniel R Budman
Capecitabine-docetaxel combination treatment.
Expert review of anticancer therapy 2006;6(9):1169-78.
2006: Daniel R Budman; Richie Soong; Anthony Calabro; Julia Tai; Robert B Diasio
Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis.
Anti-cancer drugs 2006;17(8):921-8.
2006: Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman Muss; Larry Norton; Clifford Hudis; Eric P Winer
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
JAMA : the journal of the American Medical Association 2006;295(14):1658-67.
2006: Daniel R Budman; Anthony Calabro
Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
Oncology 2006;70(2):147-53.
2005: Gary K Schwartz; Aaron Weitzman; Eileen O'Reilly; Les Brail; Dinesh P de Alwis; Ann Cleverly; Barbara Barile-Thiem; Vincent P Vinciguerra; Daniel R Budman
Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(23):5365-73.
2005: Lynn Dressler; Donald A Berry; Gloria Broadwater; David Cowan; Kelly Cox; Stephanie Griffin; Ashley Miller; Jessica Tse; Debra Novotny; Diane L Persons; Maurice Barcos; I Craig Henderson; Edison Liu; Ann D Thor; Daniel R Budman; Hyman Muss; Larry Norton; Daniel F Hayes
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(19):4287-97.
2005: Hyman Muss; Susan Woolf; Donald Berry; Constance Cirrincione; Raymond B Weiss; Daniel R Budman; William C Wood; I Craig Henderson; Clifford Hudis; Eric P Winer; Harvey Cohen; Judith Wheeler; Larry Norton
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.
JAMA : the journal of the American Medical Association 2005;293(9):1073-81.
2005: Federico Pellegrini; Daniel R Budman
Review: tubulin function, action of antitubulin drugs, and new drug development.
Cancer investigation 2005;23(3):264-73.
2004: Daniel R Budman
Dose and schedule as determinants of outcomes in chemotherapy for breast cancer.
Seminars in oncology 2004;31(6 Suppl 15):3-9.
2004: Daniel R Budman; Anthony Calabro
Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111.
Anti-cancer drugs 2004;15(9):877-81.
2003: XM Liu; Jian-Dong Jiang; Anna C Ferrari; Daniel R Budman; Long G Wang
Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells.
British journal of cancer 2003;89(8):1566-73.
2003: Samit Hirawat; Daniel R Budman; Willi Kreis
The androgen receptor: structure, mutations, and antiandrogens.
Cancer investigation 2003;21(3):400-17.
2002: Daniel R Budman; Anthony Calabro; Willi Kreis
Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro.
Anti-cancer drugs 2002;13(10):1011-6.
2002: Daniel R Budman
New directions with capecitabine combinations in advanced breast cancer.
Oncology (Williston Park, N.Y.) 2002;16(10 Suppl 12):23-8.
2002: Daniel R Budman; Anthony Calabro
In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.
Breast cancer research and treatment 2002;74(1):41-6.
2002: Jidong Shan; Liming Yuan; Daniel R Budman; Hao-Peng X. Duffy
WTH3, a new member of the Rab6 gene family, and multidrug resistance.
Biochimica et biophysica acta 2002;1589(2):112-23.
2002: Anthony J Guidi; Donald A Berry; Gloria Broadwater; Birgit Helmchen; Ira J Bleiweiss; Daniel R Budman; I Craig Henderson; Larry Norton; Daniel F Hayes
Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):732-42.
2002: Stuart M Lichtman; Erlinda Etcubanas; Daniel R Budman; Peter Eisenberg; George Zervos; Paul D'Amico; Vivian O'Mara; Kimberly Musgrave; Peter Cascella; Armen Melikian; Peter H Hinderling; Jorge M Ferrer; Gary J Williams
The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study.
Cancer investigation 2002;20(7-8):904-13.
2002: Jidong Shan; Liming Yuan; Qianxun Xiao; Nicholas Chiorazzi; Daniel R Budman; Saul Teichberg; Hao-Peng X. Duffy
TSP50, a possible protease in human testes, is activated in breast cancer epithelial cells.
Cancer research 2002;62(1):290-4.
2001: XM Liu; Long G Wang; Willi Kreis; Daniel R Budman; Laurel M Adams
Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells.
British journal of cancer 2001;85(9):1403-11.
2001: Daniel R Budman; Anthony Calabro; Willi Kreis
In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?
Leukemia 2001;15(10):1517-20.
2001: Stuart M Lichtman; Jonathan E Kolitz; Daniel R Budman; Philip Schulman; Vincent P Vinciguerra; Mark Hoffman; A Mittelman; Steven Allen; D Fusco; F A Hayes
Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP).
American journal of clinical oncology 2001;24(4):360-2.
2001: Daniel R Budman; R Johnson; B Barile; R R Bowsher; Vincent P Vinciguerra; Steven Allen; Jonathan E Kolitz; C S Ernest; Willi Kreis; P Zervos; J Walling
Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis.
Cancer chemotherapy and pharmacology 2001;47(6):525-31.
2001: Alice B Kornblith; James E Herndon; Enid Zuckerman; Catherine M Viscoli; R I Horwitz; M Robert Cooper; L Harris; Katherine Tkaczuk; M C Perry; Daniel R Budman; Larry Norton; Jimmie C Holland
Social support as a buffer to the psychological impact of stressful life events in women with breast cancer.
Cancer 2001;91(2):443-54.
2001: Willi Kreis; Daniel R Budman; Anthony Calabro
A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents.
Cancer chemotherapy and pharmacology 2001;47(1):78-82.
2000: Daniel R Budman
Capecitabine.
Investigational new drugs 2000;18(4):355-63.
2000: Jidong Shan; James M Mason; Liming Yuan; Michele Barcia; Debra Porti; Anthony Calabro; Daniel R Budman; Vincent P Vinciguerra; Hao-Peng X. Duffy
Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cells.
Gene 2000;257(1):67-75.
2000: Donald A Berry; Hyman Muss; Ann D Thor; Lynn Dressler; Edison Liu; Gloria Broadwater; Daniel R Budman; I Craig Henderson; Maurice Barcos; Daniel F Hayes; Larry Norton
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3471-9.
2000: Willi Kreis; D Petrylak; DM Savarese; Daniel R Budman
Colitis and docetaxel-based chemotherapy.
Lancet 2000;355(9221):2164.
2000: Daniel R Budman; Anthony Calabro; Long G Wang; XM Liu; L Stiel; Laurel M Adams; Willi Kreis
Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro.
Cancer investigation 2000;18(8):695-701.
1999: Willi Kreis; Daniel R Budman
Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.
Seminars in oncology 1999;26(5 Suppl 17):34-8.
1999: Long G Wang; XM Liu; Daniel R Budman; Willi Kreis
Synergistic effect of estramustine and [3'-keto-Bmtl]-[Val2]-cyclosporine (PSC 833) on the inhibition of androgen receptor phosphorylation in LNCaP cells.
Biochemical pharmacology 1999;58(7):1115-21.
1999: Rajendra N Damle; Tarun Wasil; Franco Fais; Fabio Ghiotto; Angelo Valetto; Steven Allen; A Buchbinder; Daniel R Budman; K Dittmar; Jonathan E Kolitz; Stuart M Lichtman; Philip Schulman; Vincent P Vinciguerra; Kanti Rai; Manlio Ferrarini; Nicholas Chiorazzi
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Blood 1999;94(6):1840-7.
1999: Daniel R Budman; L Weiselberg; Vivian O'Mara; A Buchbinder; Stuart M Lichtman; L Donahue; Laurel M Adams
A phase I study of sequential vinorelbine followed by paclitaxel.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(7):861-3.
1999: Long G Wang; XM Liu; Willi Kreis; Daniel R Budman
Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
Biochemical and biophysical research communications 1999;259(1):21-8.
1999: Long G Wang; XM Liu; Willi Kreis; Daniel R Budman
The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review.
Cancer chemotherapy and pharmacology 1999;44(5):355-61.
1999: Willi Kreis; Daniel R Budman; J Fetten; A L Gonzales; B Barile; Vincent P Vinciguerra
Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(1):33-8.
1999: R L Bayer; Stuart M Lichtman; Steven Allen; Daniel R Budman; A Buchbinder; J Fetten; Jonathan E Kolitz; Joseph Loscalzo
Acquired factor VIII inhibitors--successful treatment with an oral outpatient regimen.
American journal of hematology 1999;60(1):70-1.
1998: Ann D Thor; Donald A Berry; Daniel R Budman; Hyman Muss; T Kute; I Craig Henderson; Maurice Barcos; Constance Cirrincione; Susan M Edgerton; C Allred; Larry Norton; Edison Liu
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
Journal of the National Cancer Institute 1998;90(18):1346-60.
1998: Daniel R Budman; Anthony Calabro; Willi Kreis
In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents.
Anti-cancer drugs 1998;9(8):697-702.
1998: Daniel R Budman; Donald A Berry; Constance Cirrincione; I Craig Henderson; William C Wood; Raymond B Weiss; C R Ferree; Hyman Muss; Mark R Green; Larry Norton; E Frei
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.
Journal of the National Cancer Institute 1998;90(16):1205-11.
1998: Long G Wang; XM Liu; Willi Kreis; Daniel R Budman
Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.
Biochemical pharmacology 1998;55(9):1427-33.
1998: Daniel R Budman; Neal J Meropol; Bruno Reigner; Patrick J Creaven; Stuart M Lichtman; EJ Berghorn; J Behr; RJ Gordon; B Osterwalder; T Griffin
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1795-802.
1997: Daniel R Budman; Gina R Petroni; Jeffrey L Johnson; M Robert Cooper; D M Schlossman; Maurice Barcos; Bruce A Peterson
Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(10):3275-9.
1997: Long G Wang; XM Liu; Willi Kreis; Daniel R Budman
Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells.
Cancer research 1997;57(4):714-9.
1997: Willi Kreis; Daniel R Budman; Anthony Calabro
Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines.
British journal of urology 1997;79(2):196-202.
1997: Daniel R Budman
Vinorelbine (Navelbine): a third-generation vinca alkaloid.
Cancer investigation 1997;15(5):475-90.
1997: Daniel R Budman; L Weiselberg; Vivian O'Mara
Re: Severe neurotoxicity in vinorelbine-paclitaxel combinations.
Journal of the National Cancer Institute 1997;89(1):87-8.
1996: Daniel R Budman
Early studies of etoposide phosphate, a water-soluble prodrug.
Seminars in oncology 1996;23(6 Suppl 13):8-14.
1996: Franco Fais; B Sellars; Fabio Ghiotto; Joy (Xiao-Jie) Yan; Mariella Dono; Steven Allen; Daniel R Budman; K Dittmar; Jonathan E Kolitz; Stuart M Lichtman; Philip Schulman; M Schuster; Vincent P Vinciguerra; Kanti Rai; F K Stevenson; Peter K Gregersen; Manlio Ferrarini; Nicholas Chiorazzi
Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells.
The Journal of clinical investigation 1996;98(7):1659-66.
1996: W Kreis; K Chan; Daniel R Budman; Steven Allen; D Fusco; A Mittelman; K Hock; S Akerman; A Calabro; C Puccio; M Spigelman
Clinical pharmacokinetics of amonafide (NSC 308847) in 62 patients.
Cancer investigation 1996;14(4):320-7.
1996: Willi Kreis; Daniel R Budman; Vincent P Vinciguerra; K Hock; J Baer; R Ingram; L P Schacter; S Z Fields
Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors.
Cancer chemotherapy and pharmacology 1996;38(4):378-84.
1995: Prasad R K Koduru; M Susin; Jonathan E Kolitz; M Soni; S Teichberg; M J Siques; Tsieh Sun; E Amorosi; Daniel R Budman
Morphological, ultrastructural, and genetic characterization of an unusual T-cell lymphoma in a patient with sinus histiocytosis with massive lymphadenopathy.
American journal of hematology 1995;48(3):192-200.
1995: L C DeMarco; Daniel R Budman; C Lathia; P Amorusi; M Birkhofer; Stuart M Lichtman; L Weiselberg; Vincent P Vinciguerra; J Lovecchio; D Gal
Pharmacokinetic evaluation of zeniplatin in humans.
Cancer chemotherapy and pharmacology 1995;36(1):35-40.
1994: Daniel R Budman; L N Igwemezie; S Kaul; J Behr; Stuart M Lichtman; Philip Schulman; Vincent P Vinciguerra; Steven Allen; Jonathan E Kolitz; K Hock
Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(9):1902-9.
1993: Stuart M Lichtman; M J Ratain; David A Van Echo; Gary Rosner; Merrill J Egorin; Daniel R Budman; N J Vogelzang; Larry Norton; R L Schilsky
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
Journal of the National Cancer Institute 1993;85(16):1319-26.
1993: J H Marsh; Willi Kreis; B Barile; S Akerman; Philip Schulman; Steven Allen; L C DeMarco; M W Schuster; Daniel R Budman
Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin.
Cancer chemotherapy and pharmacology 1993;31(6):481-4.
1992: Daniel R Budman
New vinca alkaloids and related compounds.
Seminars in oncology 1992;19(6):639-45.
1992: Stuart M Lichtman; M Buchholtz; J Marino; Philip Schulman; Steven Allen; L Weiselberg; Daniel R Budman; L DeMarco; M Schuster; J Lovecchio
Use of cisplatin for elderly patients.
Age and ageing 1992;21(3):202-4.
1992: Willi Kreis; M Lesser; Daniel R Budman; Z Arlin; Lisa De Angelis; Paul Baskind; Eric J Feldman; S Akerman
Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response.
Cancer chemotherapy and pharmacology 1992;30(2):126-30.
1991: Willi Kreis; Daniel R Budman; K Chan; Steven Allen; Philip Schulman; Stuart M Lichtman; L Weiselberg; M Schuster; J Freeman; S Akerman
Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
Leukemia 1991;5(11):991-8.
1991: C A Puccio; A Mittelman; Stuart M Lichtman; R T Silver; Daniel R Budman; T Ahmed; Eric J Feldman; M Coleman; P M Arnold; Z A Arlin
A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(9):1562-9.
1991: Stuart M Lichtman; Daniel R Budman; H Bosworth; Steven Allen; Philip Schulman; L Weiselberg; R Weiss; D Lehrman; Vincent P Vinciguerra
Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. A pilot trial.
American journal of clinical oncology 1991;14(4):317-21.
1990: Daniel R Budman; Willi Kreis; J Behr; Philip Schulman; Stuart M Lichtman; Steven Allen; L Weiselberg; W G Satterlee; R L Nelson; Vincent P Vinciguerra
Phase I trial of intravenous vinzolidine (LY 104208) given on a biweekly dosing schedule.
Investigational new drugs 1990;8(3):269-74.
1990: Willi Kreis; Daniel R Budman; J Freeman; R F Bergstrom; R L Nelson
Clinical pharmacokinetics of intravenously injected tritiated vinzolidine.
Cancer chemotherapy and pharmacology 1990;26(6):419-22.
1989: Stuart M Lichtman; A D Seftel; M Arlen; Daniel R Budman; M Freund; M Susin; D Fagelman
Testicular malignancy associated with massive inguinal adenopathy and life threatening hemorrhage.
New York state journal of medicine 1989;89(8):482-3.
1989: L Attas; Stuart M Lichtman; Daniel R Budman; R S Verma
Trisomy 20 in acute myelogenous leukemia.
Cancer genetics and cytogenetics 1989;39(1):25-8.
1989: Z M Sthoeger; M Wakai; D B Tse; Vincent P Vinciguerra; Steven Allen; Daniel R Budman; Stuart M Lichtman; Philip Schulman; L R Weiselberg; Nicholas Chiorazzi
Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia.
The Journal of experimental medicine 1989;169(1):255-68.
1988: Willi Kreis; Daniel R Budman; P Delli Bovi; Vincent P Vinciguerra
Rapid rise of serum testosterone following discontinuation of long term treatment of prostate carcinoma with an LHRH-agonist.
Onkologie 1988;11(6):292-3.
1988: Willi Kreis; C Rottach; Daniel R Budman; K Chan; Philip Schulman; Steven Allen; L Weiselberg; Vincent P Vinciguerra
Pharmacokinetic and phase I evaluation of esorubicin (4'-deoxydoxorubicin) by continuous infusion over forty-eight hours in patients with leukemia.
Cancer research 1988;48(19):5580-4.
1988: Willi Kreis; K Chan; Daniel R Budman; Philip Schulman; Steven Allen; L Weiselberg; Stuart M Lichtman; V Henderson; J Freeman; M Deere
Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
Cancer research 1988;48(5):1337-42.
1986: Vincent P Vinciguerra; T J Degnan; A Sciortino; M O'Connell; T Moore; R Brody; Daniel R Budman; M Eng; D Carlton
A comparative assessment of home versus hospital comprehensive treatment for advanced cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(10):1521-8.
1986: Willi Kreis; Daniel R Budman; P Schulman; J Freeman; A Greist; R L Nelson; M Marks; L Kevill
Clinical pharmacology of vinzolidine.
Cancer chemotherapy and pharmacology 1986;16(1):70-4.
1985: Willi Kreis; F Chaudhri; K Chan; Steven Allen; Daniel R Budman; Philip Schulman; L Weiselberg; J Freeman; M Deere; Vincent P Vinciguerra
Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days.
Cancer research 1985;45(12 Pt 1):6498-501.
1984: A Rahman; R T Mossey; M Susin; Daniel R Budman; L U Mailloux
Kappa-chain nephropathy associated with plasma cell leukemia.
Archives of internal medicine 1984;144(8):1689-91.
1984: Daniel R Budman; Philip Schulman; M Marks; Vincent P Vinciguerra; L Weiselberg; Willi Kreis; T J Degnan
Phase I trial of vinzolidine.
Cancer treatment reports 1984;68(7-8):979-82.
1984: T Degnan; L Weiselberg; Philip Schulman; Daniel R Budman
Dysmyelopoietic syndrome. Current concepts.
The American journal of medicine 1984;76(1):122-8.
1983: Philip Schulman; Daniel R Budman; L Weiselberg; Vincent P Vinciguerra; T J Degnan
Phase II trial of mitomycin, vinblastine, and cisplatin (MVP) in non-small cell bronchogenic carcinoma.
Cancer treatment reports 1983;67(10):943-5.
1983: H Gerstein; Daniel R Budman; Philip Schulman; Vincent P Vinciguerra; T J Degnan; M Susin
Biclonal IgM gammopathy in a lymphoproliferative disorder.
Cancer 1983;52(5):824-7.
1983: Philip Schulman; N Kardon; R Weiner; Vincent P Vinciguerra; Daniel R Budman; L Weiselberg; T J Degnan
Acquired idiopathic sideroblastic anemia: a new chromosomal abnormality.
Cancer genetics and cytogenetics 1983;9(4):341-5.
1983: M Minerbrook; Daniel R Budman; Philip Schulman; Vincent P Vinciguerra; T J Degnan; E Coffey
De novo disseminated intravascular coagulation in angioimmunoblastic lymphadenopathy (AILD).
Cancer 1983;51(10):1927-30.
1982: N Kardon; Philip Schulman; T J Degnan; Daniel R Budman; J Davis; Vincent P Vinciguerra
Cytogenetic findings in the dysmyelopoietic syndrome.
Cancer 1982;50(12):2834-8.
1982: L Weiselberg; Daniel R Budman; Philip Schulman; Vincent P Vinciguerra; T J Degnan; M Pasmantier
Phase II trial of spirogermanium in advanced epithelial carcinoma of the ovary.
Cancer treatment reports 1982;66(8):1675-6.
1982: M Minerbrook; Philip Schulman; Daniel R Budman; S Teichberg; Vincent P Vinciguerra; N Kardon; T J Degnan
Burkitt's leukemia: a re-evaluation.
Cancer 1982;49(7):1444-8.
1982: Daniel R Budman; Philip Schulman; Vincent P Vinciguerra; L Weiselberg; T J Degnan
Anaphylactoid reaction due to AZQ.
Cancer chemotherapy and pharmacology 1982;8(3):317.
1982: Daniel R Budman; Philip Schulman; Vincent P Vinciguerra; T J Degnan
Phase I trial of spirogermanium given by infusion in a multiple-dose schedule.
Cancer treatment reports 1982;66(1):173-5.
1982: Philip Schulman; Daniel R Budman; Vincent P Vinciguerra; L Weiselberg; S Abrams; T Degnan
Phase II study of divided-dose vinblastine in non-small cell bronchogenic carcinoma.
Cancer treatment reports 1982;66(1):171-2.
1981: Jonathan E Kolitz; Philip Schulman; N Kardon; Daniel R Budman; Vincent P Vinciguerra; A Broekman; T J Degnan
A complex variant Philadelphia (Ph1) chromosome translocation involving chromosomes No. 11, 14, and 22 in a case of chronic myelogenous leukemia.
Cancer genetics and cytogenetics 1981;4(2):185-8.
1981: Daniel R Budman; Philip Schulman; Vincent P Vinciguerra; T Degnan
Phase II trial: mitomycin c and methotrexate combination therapy for advanced colorectal carcinoma.
Cancer treatment reports 1981;65(5-6):535.
1981: J Kross; Philip Schulman; N Kardon; Daniel R Budman; Vincent P Vinciguerra; T Degnan
Association of monosomy 7 with myelodysplasia following chemotherapy for Hodgkin's disease: serial observations.
Cancer genetics and cytogenetics 1981;3(2):155-9.
1981: L Weiselberg; S Teichberg; Vincent P Vinciguerra; Philip Schulman; Daniel R Budman; T Degnan
Electron microscope cytochemical analysis of chronic myelocytic leukemia: a case report.
Cancer 1981;47(3):533-6.
1981: L Weiselberg; Daniel R Budman; V Vinciguerra; P Schulman; T J Degnan
Tamoxifen in unresectable hypernephroma. A phase II trial and review of the literature.
Cancer clinical trials 1981;4(2):195-8.
1980: V Vinciguerra; T Degnan; J Diener; Daniel R Budman; P Schulman; J McCartney; M O'Connell; M Vargas
Home Oncology Medical Extension: a new home treatment program.
CA: a cancer journal for clinicians 1980;30(3):182-5.
1980: Philip Schulman; Daniel R Budman; Vincent P Vinciguerra; T J Degnan
Phase I evaluation of divided-dose vinblastine sulfate.
Cancer chemotherapy and pharmacology 1980;5(1):67-9.